Differential molecular mechanisms of bortezomib sensitization to rhTRAIL in non-small cell lung cancer cell lines

Paweł Kochany , Janet H. Stegehuis , Leonie H.A.M. de Wilt , Gerrit Jansen , Steven de Jong , Godefridus J. Peters , Frank A.E. Kruyt

Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002342

PDF (5749KB)
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) :1002342 DOI: 10.37349/etat.2025.1002342
Original Article
research-article
Differential molecular mechanisms of bortezomib sensitization to rhTRAIL in non-small cell lung cancer cell lines
Author information +
History +
PDF (5749KB)

Abstract

Aim: TNF-related apoptosis-inducing ligand (TRAIL) is a promising targeted anti-cancer agent for several types of cancer, including non-small cell lung cancer (NSCLC). The proteasome inhibitor bortezomib can further potentiate rhTRAIL-induced apoptosis in NSCLC cells. Here, the mechanisms underlying this sensitization were examined in TRAIL-sensitive H460 and TRAIL-resistant A549 and SW1573 NSCLC cells.

Methods: NSCLC cell lines were treated with rhTRAIL and bortezomib, and apoptosis was assessed through caspase activation assays, western blotting, and gene silencing of key apoptotic regulators, including Bid, XIAP, and cFLIP. Clonogenic assays were performed to evaluate long-term tumor growth suppression.

Results: Bortezomib sensitization mechanisms varied across NSCLC cell lines. Combined rhTRAIL/bortezomib treatment enhanced apoptosis across all cell lines. In TRAIL-sensitive H460 cells, rapid caspase activation was observed, with both extrinsic and intrinsic apoptotic pathways contributing to cell death. Sensitization in H460 cells was predominantly mediated via the caspase-8/Bid amplification loop. In A549 cells, the bortezomib sensitizing effect also relied on the caspase-8/Bid amplification loop. Additionally, the inhibition of Bid and XIAP emphasized the critical role of mitochondrial pathways in apoptosis. In SW1573 cells, limited caspase cleavage was detected, with distinct cleavage patterns suggesting cell-specific apoptotic mechanisms. In this cell line, bortezomib primarily enhanced the extrinsic apoptotic pathway, with XIAP depression further increasing apoptosis. Silencing cFLIP, a caspase-8 inhibitor, significantly improved rhTRAIL sensitivity, emphasizing the critical role of caspase-8 activation in overcoming resistance in SW1573. The clonogenic assay demonstrated that bortezomib combined with rhTRAIL significantly suppressed tumor growth, especially in resistant cell lines.
Conclusions: This study underscores bortezomib’s ability to differentially enhance rhTRAIL-induced apoptosis by targeting multiple apoptotic regulators. The variety of effects that bortezomib can exert to enhance rhTRAIL-induced apoptosis makes it a very powerful combination for the treatment of NSCLC and various other types of cancer cells.

Keywords

non-small cell lung cancer / TNF-related apoptosis-inducing ligand (TRAIL) / bortezomib / apoptosis / rhTRAIL-resistance

Cite this article

Download citation ▾
Paweł Kochany, Janet H. Stegehuis, Leonie H.A.M. de Wilt, Gerrit Jansen, Steven de Jong, Godefridus J. Peters, Frank A.E. Kruyt. Differential molecular mechanisms of bortezomib sensitization to rhTRAIL in non-small cell lung cancer cell lines. Exploration of Targeted Anti-tumor Therapy, 2025, 6 (1) : 1002342 DOI:10.37349/etat.2025.1002342

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71: 209-49.

[2]

Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021; 398: 535-54.

[3]

Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc. 2019; 94: 1623-40.

[4]

Friedlaender A, Perol M, Banna GL, Parikh K, Addeo A. Oncogenic alterations in advanced NSCLC: a molecular super-highway. Biomark Res. 2024; 12: 24.

[5]

Araghi M, Mannani R, Maleki AH, Hamidi A, Rostami S, Safa SH, et al. Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell Int. 2023; 23: 162.

[6]

Pimentel JM, Zhou J, Wu GS. The Role of TRAIL in Apoptosis and Immunosurveillance in Cancer. Cancers (Basel). 2023; 15: 2752.

[7]

Montinaro A, Walczak H. Harnessing TRAIL-induced cell death for cancer therapy: a long walk with thrilling discoveries. Cell Death Differ. 2023; 30: 237-49.

[8]

Yang C, Tseng Y, Tu Y, Kuo B, Hsu L, Lien C, et al. Reverse hierarchical DED assembly in the cFLIP-procaspase-8 and cFLIP-procaspase-8-FADD complexes. Nat Commun. 2024; 15: 8974.

[9]

Orning P, Lien E. Multiple roles of caspase-8 in cell death, inflammation, and innate immunity. J Leukoc Biol. 2021; 109: 121-41.

[10]

Zhang M, Zheng J, Nussinov R, Ma B. Release of Cytochrome C from Bax Pores at the Mitochondrial Membrane. Sci Rep. 2017; 7: 2635.

[11]

Gao Z, Tian Y, Wang J, Yin Q, Wu H, Li Y, et al. A dimeric Smac/diablo peptide directly relieves caspase-3 inhibition by XIAP. Dynamic and cooperative regulation of XIAP by Smac/Diablo. J Biol Chem. 2007; 282: 30718-27.

[12]

Kruyt FAE. TRAIL and cancer therapy. Cancer Lett. 2008; 263: 14-25.

[13]

Stegehuis JH, de Wilt LH, de Vries EG, Groen HJ, de Jong S, Kruyt FA. TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives. Drug Resist Updat. 2010; 13: 2-15.

[14]

Deng D, Shah K. TRAIL of Hope Meeting Resistance in Cancer. Trends Cancer. 2020; 6: 989-1001.

[15]

Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, et al. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res. 2007; 67: 4981-8.

[16]

Voortman J, Resende TP, Abou El Hassan MA, Giaccone G, Kruyt FA. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther. 2007; 6: 2103-12.

[17]

de Wilt LH, Kroon J, Jansen G, de Jong S, Peters GJ, Kruyt FA. Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells? Crit Rev Oncol Hematol. 2013; 85: 363-72.

[18]

Cao X, Tan J, Zheng R, Wang F, Zhou L, Yi J, et al. Targeting necroptosis: a promising avenue for respiratory disease treatment. Cell Commun Signal. 2024; 22: 418.

[19]

De Wilt L, Sobocki BK, Jansen G, Tabeian H, de Jong S, Peters GJ, et al. Mechanisms underlying reversed TRAIL sensitivity in acquired bortezomib-resistant non-small cell lung cancer cells. Cancer Drug Resist. 2024; 7: 12.

[20]

Azijli K, Xu G, Siino R, Giovanni ED, Pillai SY, Kas SM, et al. HSP90 inhibition reverses resistance to TRAIL-induced apoptosis in non-small cell lung cancer cells. Acad Oncol. : 2025; 2.

[21]

Azijli K, Weyhenmeyer B, Peters GJ, de Jong S, Kruyt FA. Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell Death Differ. 2013; 20: 858-68.

[22]

Azijli K, Yuvaraj S, van Roosmalen I, Flach K, Giovannetti E, Peters GJ, et al. MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1. Apoptosis. 2013; 18: 851-60.

[23]

Reis CR, van der Sloot AM, Natoni A, Szegezdi E, Setroikromo R, Meijer M, et al. Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. Cell Death Dis. 2010; 1: e83.

[24]

van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A, et al. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci U S A. 2006; 103: 8634-9.

[25]

Reis CR, van der Sloot AM, Szegezdi E, Natoni A, Tur V, Cool RH, et al. Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors. Biochemistry. 2009; 48: 2180-91.

[26]

de Wilt LH, Jansen G, Assaraf YG, van Meerloo J, Cloos J, Schimmer AD, et al. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer. Biochem Pharmacol. 2012; 83: 207-17.

[27]

Bijnsdorp IV, Kruyt FA, Gokoel S, Fukushima M, Peters GJ. Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent. Cancer Sci. 2008; 99: 2302-8.

[28]

Van Geelen CM, Pennarun B, Ek WB, Le PT, Spierings DC, De Vries EG, et al. Downregulation of active caspase 8 as a mechanism of acquired TRAIL resistance in mismatch repair-proficient colon carcinoma cell lines. Int J Oncol. 2010; 37: 1031-41.

[29]

Cain K, Bratton SB, Cohen GM. The Apaf-1 apoptosome: a large caspase-activating complex. Biochimie. 2002; 84: 203-14.

[30]

Sobocki BK, De Wilt LHAM, Snoek BC, Jansen G, de Jong S, Peters GJ, Kruyt FAE. Obatoclax enhances TRAIL-induced apoptosis in non-small-cell-lung-cancer cells by increasing TRAIL receptor expression, priming for mitochondrial apoptosis and reducing XIAP levels. J Cancer Metastasis Treat. 2025; 11: 13.

[31]

Danish L, Imig D, Allgöwer F, Scheurich P, Pollak N. Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps. PLoS One. 2018; 13: e0198203.

[32]

Hougardy BM, Maduro JH, van der Zee AG, de Groot DJ, van den Heuvel FA, de Vries EG, et al. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. Int J Cancer. 2006; 118: 1892-900.

[33]

Ryu S, Ahn YJ, Yoon C, Chang JH, Park Y, Kim T, et al. The regulation of combined treatment-induced cell death with recombinant TRAIL and bortezomib through TRAIL signaling in TRAIL-resistant cells. BMC Cancer. 2018; 18: 432.

[34]

Brooks AD, Jacobsen KM, Li W, Shanker A, Sayers TJ. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex. Mol Cancer Res. 2010; 8: 729-38.

[35]

Seki N, Toh U, Sayers TJ, Fujii T, Miyagi M, Akagi Y, et al. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways. Mol Cancer Ther. 2010; 9: 1842-51.

[36]

Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Herzer K, et al. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology. 2005; 42: 588-97.

[37]

Koschny R, Holland H, Sykora J, Haas TL, Sprick MR, Ganten TM, et al. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res. 2007; 13: 3403-12.

[38]

Koschny R, Ganten TM, Sykora J, Haas TL, Sprick MR, Kolb A, et al. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology. 2007; 45: 649-58.

[39]

Luster TA, Carrell JA, McCormick K, Sun D, Humphreys R. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. Mol Cancer Ther. 2009; 8: 292-302.

[40]

Yuan B, Chapman J, Reynolds SH. Proteasome inhibitors induce apoptosis in human lung cancer cells through a positive feedback mechanism and the subsequent Mcl-1 protein cleavage. Oncogene. 2009; 28: 3775-86.

[41]

Nencioni A, Wille L, Dal Bello G, Boy D, Cirmena G, Wesselborg S, et al. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells. Clin Cancer Res. 2005; 11: 4259-65.

[42]

Johnson TR, Stone K, Nikrad M, Yeh T, Zong W, Thompson CB, et al. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene. 2003; 22: 4953-63.

[43]

Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther. 2005; 4: 443-9.

[44]

Schwartz R, Davidson T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park). 2004; 18: 14-21.

[45]

Voortman J, Smit EF, Honeywell R, Kuenen BC, Peters GJ, van de Velde H, et al. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clin Cancer Res. 2007; 13: 3642-51.

[46]

Ceresa C, Giovannetti E, Voortman J, Laan AC, Honeywell R, Giaccone G, et al. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells. Mol Cancer Ther. 2009; 8: 1026-36.

[47]

Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O’Dwyer PJ, Gordon MS, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol. 2010; 28: 2839-46.

[48]

Chae SY, Kim TH, Park K, Jin C, Son S, Lee S, et al. Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther. 2010; 9: 1719-29.

[49]

Pan L, Wang H, Lai J, Xu Y, Zhang C, Chen S. Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). Biomaterials. 2013; 34: 9115-23.

[50]

LoRusso P, Ratain MJ, Doi T, Rasco DW, de Jonge MJA, Moreno V, et al. Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study. Invest New Drugs. 2022; 40: 762-72.

[51]

Loi M, Becherini P, Emionite L, Giacomini A, Cossu I, Destefanis E, et al. sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib. J Control Release. 2014; 192: 157-66.

[52]

Azijli K, van Roosmalen IA, Smit J, Pillai S, Fukushima M, de Jong S, et al. The novel thymidylate synthase inhibitor trifluorothymidine (TFT) and TRAIL synergistically eradicate non-small cell lung cancer cells. Cancer Chemother Pharmacol. 2014; 73: 1273-83.

[53]

Tahir SK, Calvo E, Carneiro BA, Yuda J, Shreenivas A, Jongen-Lavrencic M, et al. Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia. Blood. 2023; 141: 2114-26.

PDF (5749KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉